CVM

Cel-Sci Corporation develops cancer immunotherapy treatments that help the body's own immune system fight cancer cells. The company primarily works on a treatment called Multikine for head and neck cancers, which is currently in clinical trials. They make money through research funding, clinical trial partnerships, and would generate revenue from drug sales if their treatments receive regulatory approval and reach the market.